XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access
via the World Wide Web to its presentation at the Morgan Stanley Global
Healthcare Unplugged Conference. The live presentation will occur at
8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) on Tuesday, September
9, 2008. A replay of the presentation will also be available.
To access the live presentation via the Web, please go to www.XenoPort.com.
Please connect to the Web site at least 15 minutes prior to the live
presentation to ensure adequate time for any software downloads that may
be necessary to listen to the Webcast.
A replay of the Webcast can be accessed for a minimum of one week and
will be available approximately 24 hours after the live presentation.
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a
portfolio of internally discovered product candidates that utilize the
body’s natural nutrient transport mechanisms
to improve the therapeutic benefits of existing drugs. Its development
and commercialization efforts are currently focused on potential
treatments of central nervous system disorders. XenoPort’s
most advanced product candidate, XP13512, which is known as Solzira™
in the United States, has successfully completed three pivotal trials in
its Phase 3 clinical program for the treatment of moderate-to-severe
primary restless legs syndrome, or RLS. It has also successfully
completed a Phase 2a clinical trial for the management of post-herpetic
neuralgia and is currently being evaluated by XenoPort’s
partners, Astellas Pharma Inc. and GlaxoSmithKline, in Phase 2 clinical
trials as a potential treatment for neuropathic pain and by Astellas in
a Phase 2 clinical trial as a potential treatment for RLS. XenoPort has
reported positive results from a Phase 2a clinical trial of its second
product candidate, XP19986, in patients with gastroesophageal reflux
disease, or GERD, and is currently conducting a second Phase 2 clinical
trial in GERD patients. It is also evaluating XP19986 as a potential
treatment of patients with spasticity related to spinal cord injury.
XenoPort’s third product candidate, XP21279,
has been evaluated in a Phase 1 clinical trial that produced positive
data regarding its use as a potential treatment for Parkinson’s
disease.
To learn more about XenoPort, please visit the Web site at www.XenoPort.com.
XenoPort is a registered trademark of XenoPort, Inc.
Solzira is a U.S. trademark of GlaxoSmithKline.
XNPT2G
XenoPort, Inc.
Jackie Cossmon, 408-616-7220
ir@XenoPort.com
